The Pennsylvania State University
Intellectual Property
Targepeutics has a strong and growing relationship with The Pennsylvania State University. The Company has executed an exclusive license agreement with The Penn State Research Foundation for key technologies emanating from work in the lab of Dr. Debinski. At the University’s request, an agreement has been negotiated to convert Penn State’s interest into equity in Targepeutics. We are pleased to be partnering with such a reputable University with an annual research budget exceeding $440MM.
Back to Top
New Approaches to Brain Tumor Therapy (NABTT) Consortium
In recognition of Dr. Debinski’s record in experimental therapeutics, he and Targepeutics have been invited to participate in the New Approaches to Brain Tumor Therapy (NABTT) Consortium which consists of leading oncologists, neurologists and neurosurgeons. The primary goals of the NABTT Consortium are to develop scientific advances and improve therapeutic outcomes for patients with primary brain tumors.
NABTT Is NCI-Funded
This exemplary program is a National Cancer Institute (NCI)-funded clinical consortium of the following 10 top cancer treatment institutions with outstanding multidisciplinary expertise, innovative clinical and laboratory research capabilities, and access to a large patient population with brain tumors.
| Emory University |
Johns Hopkins University |
University of Texas |
| University of Alabama |
H. Lee Moffitt Cancer Center |
Henry Ford Hospital |
| University of Pennsylvania |
Massachusetts General Hospital |
Wake Forest University
|
| The Cleveland Clinic |
|
|
NCI funding enables companies sponsored by NABTT to cut clinical trial costs. Currently, Targepeutics and NABTT are jointly designing clinical protocols to quickly evaluate the toxicity and efficacy of Glioblast-13 in Phase I/Phase II clinical trials.
Back to Top
Sterne, Kessler, Goldstein & Fox
Targepeutics is pleased to have on its team, intellectual property attorneys of such high regard in their community. These strategists and advisors specialize in the protection, transfer and enforcement of Targepeutics' Intellectual Property Rights. The team is lead by Dr. Jorge Goldstein and is located in Washington, D.C.
Back to Top
The National Cancer Institute
SBIR Grant Award
The National Cancer Institute recently awarded Targepeutics a $100,000 Small Business Innovative Research (SBIR) grant to develop GB-13, the Company’s first brain cancer compound. This grant is a Phase I award and makes Targepeutics eligible to submit for up to $2 million in Phase II of the program.
Extramural Funding Program Interest
The Company may also have the opportunity to work with the National Cancer Institute’s extramural research branch to develop the Company’s second brain cancer compound, TRIGLIO. |
 |
Back to Top
The Constella Group
Targepeutics has contracted with the Constella Group as its contract research organization. Located in Research Triangle Park in North Carolina, the firm was founded, and is staffed predominantly by former Glaxo-Wellcome employees with extensive experience in the regulatory process of cancer compounds. Constella provides complete development capabilities from IND application to NDA approval and post-marketing. They will file for Orphan and Fast-Track status with our IND submission. In addition to managing clinical trials, Constella provides clients with high level scientific and regulatory consulting services and a proven expertise in scientific writing and communications.
Back to Top
FDA
Targepeutics maintains a positive working relationship through pre-IND meetings with the FDA (Food and Drug Administration), which has defined achievable milestones for GB-13's path to clinical trials. Targepeutics will file for both Fast Track and Orphan Drug status concomitantly with its Investigational New Drug Application.
Back to Top |
